Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.

di Martino E, Alder O, Hurst CD, Knowles MA.

Sci Rep. 2019 Apr 5;9(1):5740. doi: 10.1038/s41598-018-36456-3.

2.

Mutational landscape of non-muscle-invasive bladder cancer.

Hurst CD, Knowles MA.

Urol Oncol. 2018 Nov 13. pii: S1078-1439(18)30398-3. doi: 10.1016/j.urolonc.2018.10.015. [Epub ahead of print] Review.

3.

FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.

Foth M, Ismail NFB, Kung JSC, Tomlinson D, Knowles MA, Eriksson P, Sjödahl G, Salmond JM, Sansom OJ, Iwata T.

J Pathol. 2018 Nov;246(3):331-343. doi: 10.1002/path.5143. Epub 2018 Sep 19.

4.

Patient-derived mutations within the N-terminal domains of p85α impact PTEN or Rab5 binding and regulation.

Mellor P, Marshall JDS, Ruan X, Whitecross DE, Ross RL, Knowles MA, Moore SA, Anderson DH.

Sci Rep. 2018 May 8;8(1):7108. doi: 10.1038/s41598-018-25487-5.

5.

Unique signalling connectivity of FGFR3-TACC3 oncoprotein revealed by quantitative phosphoproteomics and differential network analysis.

Lombardi B, Ashford P, Moya-Garcia AA, Rust A, Crawford M, Williams SV, Knowles MA, Katan M, Orengo C, Godovac-Zimmermann J.

Oncotarget. 2017 Oct 25;8(61):102898-102911. doi: 10.18632/oncotarget.22048. eCollection 2017 Nov 28.

6.

Identification of an Indazole-Based Pharmacophore for the Inhibition of FGFR Kinases Using Fragment-Led de Novo Design.

Turner LD, Summers AJ, Johnson LO, Knowles MA, Fishwick CWG.

ACS Med Chem Lett. 2017 Nov 11;8(12):1264-1268. doi: 10.1021/acsmedchemlett.7b00349. eCollection 2017 Dec 14.

7.

Bladder cancer: Multi-omic profiling refines the molecular view.

Hurst CD, Knowles MA.

Nat Rev Clin Oncol. 2018 Apr;15(4):203-204. doi: 10.1038/nrclinonc.2017.195. Epub 2017 Dec 19. No abstract available.

8.

Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency.

Hurst CD, Alder O, Platt FM, Droop A, Stead LF, Burns JE, Burghel GJ, Jain S, Klimczak LJ, Lindsay H, Roulson JA, Taylor CF, Thygesen H, Cameron AJ, Ridley AJ, Mott HR, Gordenin DA, Knowles MA.

Cancer Cell. 2017 Nov 13;32(5):701-715.e7. doi: 10.1016/j.ccell.2017.08.005.

9.

TRPA1-FGFR2 binding event is a regulatory oncogenic driver modulated by miRNA-142-3p.

Berrout J, Kyriakopoulou E, Moparthi L, Hogea AS, Berrout L, Ivan C, Lorger M, Boyle J, Peers C, Muench S, Gomez JE, Hu X, Hurst C, Hall T, Umamaheswaran S, Wesley L, Gagea M, Shires M, Manfield I, Knowles MA, Davies S, Suhling K, Gonzalez YT, Carragher N, Macleod K, Abbott NJ, Calin GA, Gamper N, Zygmunt PM, Timsah Z.

Nat Commun. 2017 Oct 16;8(1):947. doi: 10.1038/s41467-017-00983-w.

10.

Bladder cancer.

Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y.

Nat Rev Dis Primers. 2017 Apr 13;3:17022. doi: 10.1038/nrdp.2017.22. Review.

11.

Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup.

Baldia PH, Maurer A, Heide T, Rose M, Stoehr R, Hartmann A, Williams SV, Knowles MA, Knuechel R, Gaisa NT.

Oncotarget. 2016 Nov 1;7(44):71429-71439. doi: 10.18632/oncotarget.12198.

12.

PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.

Ross RL, McPherson HR, Kettlewell L, Shnyder SD, Hurst CD, Alder O, Knowles MA.

BMC Cancer. 2016 Jul 28;16:553. doi: 10.1186/s12885-016-2570-0.

13.

A place for precision medicine in bladder cancer: targeting the FGFRs.

di Martino E, Tomlinson DC, Williams SV, Knowles MA.

Future Oncol. 2016 Oct;12(19):2243-63. doi: 10.2217/fon-2016-0042. Epub 2016 Jul 6. Review.

14.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW.

Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18.

15.

Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.

Patani H, Bunney TD, Thiyagarajan N, Norman RA, Ogg D, Breed J, Ashford P, Potterton A, Edwards M, Williams SV, Thomson GS, Pang CS, Knowles MA, Breeze AL, Orengo C, Phillips C, Katan M.

Oncotarget. 2016 Apr 26;7(17):24252-68. doi: 10.18632/oncotarget.8132.

16.

Polycomb Repressor Complex 1 Member, BMI1 Contributes to Urothelial Tumorigenesis through p16-Independent Mechanisms.

De Faveri LE, Hurst CD, Roulson JA, Wood H, Sanchez-Carbayo M, Knowles MA, Chapman EJ.

Transl Oncol. 2015 Oct;8(5):387-99. doi: 10.1016/j.tranon.2015.08.002.

17.

Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms.

Burghel GJ, Hurst CD, Watson CM, Chambers PA, Dickinson H, Roberts P, Knowles MA.

Biomed Res Int. 2015;2015:478017. doi: 10.1155/2015/478017. Epub 2015 Aug 17.

18.

Use of Aleuria alantia Lectin Affinity Chromatography to Enrich Candidate Biomarkers from the Urine of Patients with Bladder Cancer.

Ambrose SR, Gordon NS, Goldsmith JC, Wei W, Zeegers MP, James ND, Knowles MA, Bryan RT, Ward DG.

Proteomes. 2015 Sep 3;3(3):266-282. doi: 10.3390/proteomes3030266.

19.

The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study.

Bunney TD, Wan S, Thiyagarajan N, Sutto L, Williams SV, Ashford P, Koss H, Knowles MA, Gervasio FL, Coveney PV, Katan M.

EBioMedicine. 2015 Mar 1;2(3):194-204.

20.

Frequency of TERT Promoter Mutations in Prostate Cancer.

Stoehr R, Taubert H, Zinnall U, Giedl J, Gaisa NT, Burger M, Ruemmele P, Hurst CD, Knowles MA, Wullich B, Hartmann A.

Pathobiology. 2015;82(2):53-7. doi: 10.1159/000381903. Epub 2015 May 21.

21.

Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM.

Bryan RT, Regan HL, Pirrie SJ, Devall AJ, Cheng KK, Zeegers MP, James ND, Knowles MA, Ward DG.

Br J Cancer. 2015 Mar 17;112(6):1052-8. doi: 10.1038/bjc.2015.21.

22.

Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.

Knowles MA, Hurst CD.

Nat Rev Cancer. 2015 Jan;15(1):25-41. doi: 10.1038/nrc3817. Review.

23.

Alteration of cell-cell and cell-matrix adhesion in urothelial cells: an oncogenic mechanism for mutant FGFR3.

di Martino E, Kelly G, Roulson JA, Knowles MA.

Mol Cancer Res. 2015 Jan;13(1):138-48. doi: 10.1158/1541-7786.MCR-14-0022. Epub 2014 Sep 15.

24.

Assessing the quality of studies on the diagnostic accuracy of tumor markers.

Goebell PJ, Kamat AM, Sylvester RJ, Black P, Droller M, Godoy G, Hudson MA, Junker K, Kassouf W, Knowles MA, Schulz WA, Seiler R, Schmitz-Dräger BJ.

Urol Oncol. 2014 Oct;32(7):1051-60. doi: 10.1016/j.urolonc.2013.10.003. Epub 2014 Aug 20. Review.

25.

FGFR3 expression in primary invasive bladder cancers and matched lymph node metastases.

Turo R, Harnden P, Thygesen H, Fleischmann A, Thalmann GN, Seiler R, Cross WR, Knowles MA.

J Urol. 2015 Jan;193(1):325-30. doi: 10.1016/j.juro.2014.06.026. Epub 2014 Jun 13.

26.

Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer.

Rafnar T, Sulem P, Thorleifsson G, Vermeulen SH, Helgason H, Saemundsdottir J, Gudjonsson SA, Sigurdsson A, Stacey SN, Gudmundsson J, Johannsdottir H, Alexiusdottir K, Petursdottir V, Nikulasson S, Geirsson G, Jonsson T, Aben KK, Grotenhuis AJ, Verhaegh GW, Dudek AM, Witjes JA, van der Heijden AG, Vrieling A, Galesloot TE, De Juan A, Panadero A, Rivera F, Hurst C, Bishop DT, Sak SC, Choudhury A, Teo MT, Arici C, Carta A, Toninelli E, de Verdier P, Rudnai P, Gurzau E, Koppova K, van der Keur KA, Lurkin I, Goossens M, Kellen E, Guarrera S, Russo A, Critelli R, Sacerdote C, Vineis P, Krucker C, Zeegers MP, Gerullis H, Ovsiannikov D, Volkert F, Hengstler JG, Selinski S, Magnusson OT, Masson G, Kong A, Gudbjartsson D, Lindblom A, Zwarthoff E, Porru S, Golka K, Buntinx F, Matullo G, Kumar R, Mayordomo JI, Steineck DG, Kiltie AE, Jonsson E, Radvanyi F, Knowles MA, Thorsteinsdottir U, Kiemeney LA, Stefansson K.

Hum Mol Genet. 2014 Oct 15;23(20):5545-57. doi: 10.1093/hmg/ddu264. Epub 2014 May 26.

27.

FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.

Acquaviva J, He S, Zhang C, Jimenez JP, Nagai M, Sang J, Sequeira M, Smith DL, Ogawa LS, Inoue T, Tatsuta N, Knowles MA, Bates RC, Proia DA.

Mol Cancer Res. 2014 Jul;12(7):1042-54. doi: 10.1158/1541-7786.MCR-14-0004. Epub 2014 Apr 30.

28.

Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer.

Teo MT, Dyrskjøt L, Nsengimana J, Buchwald C, Snowden H, Morgan J, Jensen JB, Knowles MA, Taylor G, Barrett JH, Borre M, Orntoft TF, Bishop DT, Kiltie AE.

Ann Oncol. 2014 Apr;25(4):877-83. doi: 10.1093/annonc/mdu014. Epub 2014 Mar 12.

29.

Molecular subtyping of invasive bladder cancer: time to divide and rule?

Hurst CD, Knowles MA.

Cancer Cell. 2014 Feb 10;25(2):135-6. doi: 10.1016/j.ccr.2014.01.026.

30.

The use of a neutral peptide aptamer scaffold to anchor BH3 peptides constitutes a viable approach to studying their function.

Stadler LK, Tomlinson DC, Lee T, Knowles MA, Ko Ferrigno P.

Cell Death Dis. 2014 Jan 30;5:e1037. doi: 10.1038/cddis.2013.564.

31.

Identification of mutations in distinct regions of p85 alpha in urothelial cancer.

Ross RL, Burns JE, Taylor CF, Mellor P, Anderson DH, Knowles MA.

PLoS One. 2013 Dec 18;8(12):e84411. doi: 10.1371/journal.pone.0084411. eCollection 2013.

32.

Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes.

Taylor CF, Platt FM, Hurst CD, Thygesen HH, Knowles MA.

Hum Mol Genet. 2014 Apr 15;23(8):1964-74. doi: 10.1093/hmg/ddt589. Epub 2013 Nov 22.

33.

Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

Hurst CD, Platt FM, Knowles MA.

Eur Urol. 2014 Feb;65(2):367-9. doi: 10.1016/j.eururo.2013.08.057. Epub 2013 Sep 3. No abstract available.

PMID:
24035680
34.

Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer.

Blick C, Ramachandran A, Wigfield S, McCormick R, Jubb A, Buffa FM, Turley H, Knowles MA, Cranston D, Catto J, Harris AL.

Br J Cancer. 2013 Jul 9;109(1):50-9. doi: 10.1038/bjc.2013.240. Epub 2013 Jun 18.

35.

An integrated genomic, transcriptional and protein investigation of FGFRL1 as a putative 4p16.3 deletion target in bladder cancer.

di Martino E, Taylor CF, Roulson JA, Knowles MA.

Genes Chromosomes Cancer. 2013 Sep;52(9):860-71. doi: 10.1002/gcc.22082. Epub 2013 Jun 14.

36.

Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.

Herrera-Abreu MT, Pearson A, Campbell J, Shnyder SD, Knowles MA, Ashworth A, Turner NC.

Cancer Discov. 2013 Sep;3(9):1058-71. doi: 10.1158/2159-8290.CD-12-0569. Epub 2013 Jun 6.

37.

Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer.

De Faveri LE, Hurst CD, Platt FM, Taylor CF, Roulson JA, Sanchez-Carbayo M, Knowles MA, Chapman EJ.

Br J Cancer. 2013 Apr 2;108(6):1368-77. doi: 10.1038/bjc.2013.104.

38.

Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers.

Wood SL, Knowles MA, Thompson D, Selby PJ, Banks RE.

Nat Rev Urol. 2013 Apr;10(4):206-18. doi: 10.1038/nrurol.2013.24. Epub 2013 Feb 26. Review.

PMID:
23443013
39.

Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker.

Morgan R, Bryan RT, Javed S, Launchbury F, Zeegers MP, Cheng KK, James ND, Wallace DM, Hurst CD, Ward DG, Knowles MA, Pandha H.

Eur J Cancer. 2013 Jun;49(9):2214-22. doi: 10.1016/j.ejca.2013.01.019. Epub 2013 Feb 21.

PMID:
23434148
40.

Desmoid fibromatosis in children and adolescents: a conservative approach to management.

Honeyman JN, Theilen TM, Knowles MA, McGlynn MM, Hameed M, Meyers P, Crago AM, La Quaglia MP.

J Pediatr Surg. 2013 Jan;48(1):62-6. doi: 10.1016/j.jpedsurg.2012.10.017.

PMID:
23331794
41.

Imatinib radiosensitizes bladder cancer by targeting homologous recombination.

Qiao B, Kerr M, Groselj B, Teo MT, Knowles MA, Bristow RG, Phillips RM, Kiltie AE.

Cancer Res. 2013 Mar 1;73(5):1611-20. doi: 10.1158/0008-5472.CAN-12-1170. Epub 2013 Jan 9.

42.

Oncogenic FGFR3 gene fusions in bladder cancer.

Williams SV, Hurst CD, Knowles MA.

Hum Mol Genet. 2013 Feb 15;22(4):795-803. doi: 10.1093/hmg/dds486. Epub 2012 Nov 21.

43.

Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis.

Hurst CD, Platt FM, Taylor CF, Knowles MA.

Clin Cancer Res. 2012 Nov 1;18(21):5865-5877. doi: 10.1158/1078-0432.CCR-12-1807. Epub 2012 Aug 29.

44.

A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges.

di Martino E, Tomlinson DC, Knowles MA.

Adv Urol. 2012;2012:429213. doi: 10.1155/2012/429213. Epub 2012 Jul 31.

45.

Factors associated with relapse and survival in Wilms tumor: a multivariate analysis.

Honeyman JN, Rich BS, McEvoy MP, Knowles MA, Heller G, Riachy E, Kobos R, Shukla N, Wolden SL, Steinherz PG, La Quaglia MP.

J Pediatr Surg. 2012 Jun;47(6):1228-33. doi: 10.1016/j.jpedsurg.2012.03.030. Review.

PMID:
22703798
46.

FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms.

Tomlinson DC, Baxter EW, Loadman PM, Hull MA, Knowles MA.

PLoS One. 2012;7(6):e38972. doi: 10.1371/journal.pone.0038972. Epub 2012 Jun 12.

47.

PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.

Ross RL, Askham JM, Knowles MA.

Oncogene. 2013 Feb 7;32(6):768-76. doi: 10.1038/onc.2012.87. Epub 2012 Mar 19.

PMID:
22430209
48.

A meckelin-filamin A interaction mediates ciliogenesis.

Adams M, Simms RJ, Abdelhamed Z, Dawe HR, Szymanska K, Logan CV, Wheway G, Pitt E, Gull K, Knowles MA, Blair E, Cross SH, Sayer JA, Johnson CA.

Hum Mol Genet. 2012 Mar 15;21(6):1272-86. doi: 10.1093/hmg/ddr557. Epub 2011 Nov 25.

49.

Mechanisms of FGFR3 actions in endocrine resistant breast cancer.

Tomlinson DC, Knowles MA, Speirs V.

Int J Cancer. 2012 Jun 15;130(12):2857-66. doi: 10.1002/ijc.26304. Epub 2011 Aug 29.

50.

European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene.

Rafnar T, Vermeulen SH, Sulem P, Thorleifsson G, Aben KK, Witjes JA, Grotenhuis AJ, Verhaegh GW, Hulsbergen-van de Kaa CA, Besenbacher S, Gudbjartsson D, Stacey SN, Gudmundsson J, Johannsdottir H, Bjarnason H, Zanon C, Helgadottir H, Jonasson JG, Tryggvadottir L, Jonsson E, Geirsson G, Nikulasson S, Petursdottir V, Bishop DT, Chung-Sak S, Choudhury A, Elliott F, Barrett JH, Knowles MA, de Verdier PJ, Ryk C, Lindblom A, Rudnai P, Gurzau E, Koppova K, Vineis P, Polidoro S, Guarrera S, Sacerdote C, Panadero A, Sanz-Velez JI, Sanchez M, Valdivia G, Garcia-Prats MD, Hengstler JG, Selinski S, Gerullis H, Ovsiannikov D, Khezri A, Aminsharifi A, Malekzadeh M, van den Berg LH, Ophoff RA, Veldink JH, Zeegers MP, Kellen E, Fostinelli J, Andreoli D, Arici C, Porru S, Buntinx F, Ghaderi A, Golka K, Mayordomo JI, Matullo G, Kumar R, Steineck G, Kiltie AE, Kong A, Thorsteinsdottir U, Stefansson K, Kiemeney LA.

Hum Mol Genet. 2011 Nov 1;20(21):4268-81. doi: 10.1093/hmg/ddr303. Epub 2011 Jul 12.

Supplemental Content

Loading ...
Support Center